Fredun Pharmaceuticals: Financial results for the quarter ended 30th September, 2026
Fredun Pharmaceuticals (FREDUN) filed a disclosure titled "Financial results for the quarter ended 30th September, 2026". The company is valued at about ₹2,550 crore.
What happened
Fredun Pharmaceuticals (FREDUN) filed a disclosure with the exchanges on 5 November 2026 at 11:31 AM titled "Financial results for the quarter ended 30th September, 2026".
Company snapshot
Fredun Pharmaceuticals is a small-cap company, with a market value of about ₹2,550 crore.
The stock last traded at ₹1,542, against a 52-week range of ₹1,195.2–₹1,665 (7.4% below the high).
Before this filing the shares had moved +10.7% over the month. Average daily turnover over the last 20 sessions was about ₹23.05 crore.
Promoters held 44.57% at the end of Q2 FY27. Foreign institutions owned 1.06% and domestic institutions 2.94%.
| Quarter | Revenue | Net profit | EPS (₹) |
|---|---|---|---|
| Q1 FY26 | 119 | 6.8 | 14.33 |
| Q2 FY26 | 144 | 9.7 | 20.61 |
| Q3 FY26 | 160 | 10.5 | 19.53 |
| Q4 FY26 | 210 | 11.1 | 20.22 |
| Q1 FY27 | 228 | 13.2 | 23.89 |
What history shows
BCEIE's records show 4 previous results filings from the company since May 2026.
Market-wide, 10,790 results filings with an impact score of 50 or more saw an average next-day move of −0.3%, with 42% rising.
Past reactions describe what happened before; they are not a forecast.
What to watch
- Management commentary, margins and order book or guidance in the investor presentation.
In the news
Recent coverage elsewhere (links open the original publisher):
Source
Automatically written from the exchange filing and BCEIE data. Not investment advice. Check the original filing before acting on it.